Galcanezumab
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Galcanezumab: Heparin cofactor 2 deficiency
One-Sentence Summary
Galcanezumab is an anti-CGRP monoclonal antibody originally used to prevent migraine. The TxGNN model predicts it may be effective for migraine with brainstem aura, a migraine subtype, with no registered clinical trials specific to this subtype but 20 publications supporting the broader anti-CGRP direction (including Phase 3 RCT data in episodic migraine).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Heparin cofactor 2 deficiency |
| TxGNN Prediction Score | 0.9950 |
| Evidence Level | L5 (based on Phase 3 RCTs in broader migraine; subtype-specific evidence is limited) |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Proceed with Guardrails |
Note on other predictions: The model ranked several coagulation-related conditions highest by score (heparin cofactor 2 deficiency 0.9950, antithrombin deficiency type 2 0.9941, factor 5 excess with spontaneous thrombosis 0.9941). None has any supporting trial or publication, and none has a plausible link to CGRP blockade. These scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. They are rated Hold.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, galcanezumab is a humanised monoclonal antibody that binds calcitonin gene-related peptide (CGRP) and inhibits its activity. CGRP is a key mediator of trigeminovascular activation in migraine.
Migraine with brainstem aura is a subtype of migraine, and galcanezumab is already used for migraine prevention. This is therefore an extension within the original indication rather than true repurposing. Emerging literature on anti-CGRP antibodies in migraine aura and in genetic or hemiplegic migraine (for example PMID 38091211, 40341526, 41618146) is supportive but not definitive.
Subtype-specific efficacy in brainstem aura has not been established in dedicated trials, and patients with these aura subtypes have often been excluded from RCTs.
Clinical Trial Evidence
Currently no related clinical trials registered for migraine with brainstem aura in the data compiled for this report. No ANZCTR identifiers were identified.
Literature Evidence
The compiled data include 20 publications. The most relevant are listed below (RCTs first, then reviews and observational studies).
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29813147 | 2018 | RCT | JAMA Neurol | EVOLVE-1 Phase 3 trial of galcanezumab for prevention of episodic migraine |
| 33549036 | 2021 | RCT (pooled post-hoc, Phase 3) | J Headache Pain | EVOLVE-1, EVOLVE-2 and REGAIN: effect on migraine severity and symptoms in episodic and chronic migraine |
| 36266558 | 2023 | RCT (secondary analysis) | Neurol Ther | Japanese Phase 2 trial: effect on migraine severity and associated symptoms |
| 32504377 | 2020 | Review | Drugs | Galcanezumab significantly more effective than placebo in episodic and chronic migraine prevention, and in episodic cluster headache |
| 41618146 | 2026 | Systematic review | J Headache Pain | Effectiveness and safety of anti-CGRP antibodies in hemiplegic migraine (individual patient analysis) |
| 38091211 | 2024 | Observational cohort (pilot) | Neurol Sci | Pilot study of anti-CGRP antibodies for migraine aura |
| 38332541 | 2024 | Case series | CNS Neurosci Ther | Effect of anti-CGRP therapy on migraine aura |
| 40341526 | 2025 | Case series | Headache | Two genetic conditions with prominent migraine responded to CGRP antagonist therapy |
| 37366160 | 2023 | Case series | Headache | Anti-CGRP antibodies in hemiplegic migraine |
| 42390441 | 2026 | Cohort (pharmacoepidemiology) | Cephalalgia | Cerebrovascular risk (ischaemic stroke/TIA) with CGRP antibodies versus onabotulinumtoxinA |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 12469G | Emgality | Injection 120 mg in 1 mL pre-filled pen | Not available in the compiled data |
Safety Considerations
- Vascular safety: A case report describes cerebral artery vasoconstriction after a galcanezumab loading dose (PMID 39365416), and CGRP blockade carries theoretical ischaemic concerns. A real-world cohort study has examined stroke/TIA risk against onabotulinumtoxinA (PMID 42390441), and a multinational cohort study has examined glaucoma risk with CGRP inhibitors (PMID 42090640). Caution is warranted in brainstem aura, where ischaemic concerns are theoretical.
Please refer to the TGA-approved Product Information (PI) for full warnings, contraindications and drug interaction information. No drug interaction records were found in the compiled data.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale:
- Galcanezumab already has Phase 3 RCT support in migraine and is marketed in Australia. Migraine with brainstem aura is a migraine subtype, so this is an in-class extension. Subtype-specific evidence is limited to small observational studies and case series. All other model predictions (coagulation and skin conditions) lack any supporting evidence or mechanistic plausibility and should be held.
To proceed, the following is needed:
- Subtype-specific efficacy data for brainstem aura (a dedicated trial or well-designed registry)
- Mechanism of action data and the approved indication text for the ARTG entry
- Review of the PI for warnings and contraindications
- A cardiovascular and cerebrovascular monitoring plan, given the theoretical ischaemic concerns
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.